AVX 470
Alternative Names: Avaximab-TNF; AVX-1350; AVX-470; AVX-470hLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Avaxia Biologics
- Class Polyclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute radiation syndrome; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Belgium (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Canada (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Hungary (PO, Capsule)